• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Drug Compounding Pharmacies: Risks & Oversight Issues

Drug Compounding Pharmacies: Risks & Oversight Issues

9781628081763
661,44 zł
595,29 zł Zniżka 66,15 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 595,29 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
In light of the 2012 fungal meningitis outbreak, believed to have been caused by a contaminated compounded steroid injection, the regulation of human drug compounding has received significant attention. Drug compounding in its traditional form is the process of combining, mixing, or altering ingredients in order to create a medication for a particular patient. However, as illustrated by the entity that created the steroid medication linked with the meningitis outbreak, concerns have been raised about compounding pharmacies producing drugs on a larger scale. While drug compounding has historically been the focus of state governments through their regulation of pharmacies, questions have arisen regarding the extent the federal government can regulate the practice of compounding through the Food, Drug, and Cosmetic Act (FDCA). This book examines the FDAs regulation of drug compounding and discusses relevant legal authorities, and the potential limits to the FDAs authority to regulate human drug compounding.
Szczegóły produktu
74281
9781628081763
9781628081763

Opis

Rok wydania
2013
Numer wydania
1
Oprawa
twarda
Liczba stron
137
Wymiary (mm)
155.00 x 230.00
Waga (g)
386
  • Preface; Federal Authority to Regulate the Compounding of Human Drugs; FDAs Authority to Regulate Drug Compounding:: A Legal Analysis; State of Disarray:: How States Inability to Oversee Compounding Pharmacies Puts Public Health at Risk; Compounding Pharmacies, Compounding Risk; The New England Compounding Center & the Meningitis Outbreak of 2012:: A Failure to Address Risk to the Public Health; Selected Resources on Federal Oversight of Compounding Pharmacies; Index.
Komentarze (0)